Immunoglobulin A antibody to Epstein-Barr viral antigens and prognosis in nasopharyngeal carcinoma.
IgA immunoglobulin fractions containing antibodies to Epstein-Barr virus (EBV)-induced membrane antigens were isolated from the sera of two patients with nasopharyngeal carcinoma (NPC), from one non-NPC patient, and from three persons with sera negative for IgA antibodies. IgA antibodies were not cytotoxic against cells expressing EBV-induced membrane antigens in the antibody-dependent cellular cytotoxicity (ADCC) assay. However, IgA antibodies blocked IgG-mediated ADCC, which indicated that these antibodies could serve as a blocking "factor" in patients with disease and, therefore, were potentially detrimental to the host.
D000914:Antibodies, Viral / Q000276:immunology*; D000956:Antigens, Viral / Q000276:immunology*; D001667:Binding, Competitive; D003601:Cytotoxicity Tests, Immunologic; D004854:Herpesvirus 4, Human / Q000276:immunology*; D006801:Humans; D007070:Immunoglobulin A / Q000032:analysis / Q000276:immunology*; D007074:Immunoglobulin G / Q000032:analysis / Q000276:immunology; D009303:Nasopharyngeal Neoplasms / Q000276:immunology* / Q000628:therapy; D011379:Prognosis
D000914:Antibodies, Viral; D000956:Antigens, Viral; D007070:Immunoglobulin A; D007074:Immunoglobulin G